Intact Genomics Inc Profile last edited on: 9/21/2022
CAGE: 6ZS47
UEI: ZR9GABSXHMY8
Business Identifier: Large DNA fragment cloning and metagenomic technologies 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1100 Corporate Square Drive Suite 257
Saint Louis, MO 63132
Saint Louis, MO 63132
| (314) 942-3655 |
| sales@intactgenomics.com |
| www.intactgenomics.com |
Location: Single
Congr. District: 01
County: St. Louis
Congr. District: 01
County: St. Louis
Public Profile
Provides high-quality life science products and large DNA fragment cloning related services, Intact Genomic is organized around enabling scientists to explore the genome structure and function of microorganisms, plants, and animal species. Founded and headed up by early and long time involved in the space, the firm offers high-quality life science products and large insert DNA cloning, manipulation, and BAC library related services. The firm's principals also apply BAC related technologies in metagenomic research to develop new solutions for agricultural research, natural product-enzyme discovery, and environmental protection. The firm has expertise in high molecular weight (HMW) genomic DNA preparation, large DNA fragment manipulation, bacterial artificial chromosome (BAC) cloning, and unbiased BAC library construction.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 2 | NIH | $2,942,798 | |
| Project Title: Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes | ||||
| 2023 | 1 | NIH | $300,156 | |
| Project Title: A Platform to Identify Antifungal Compounds with Novel Action Mechanisms | ||||
| 2022 | 2 | NIH | $3,300,000 | |
| Project Title: Rapid Discovery of Thousands of Intact Biosynthetic Gene Pathways for Bioactive Natural Product Compounds from Un-Sequenced Filamentous Fungi Using a Novel Fac-Ngs Tool | ||||
| 2019 | 2 | NIH | $1,721,098 | |
| Project Title: A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans | ||||
| 2018 | 1 | NIH | $229,472 | |
| Project Title: Rapid Dissection of the Biosynthesis of Antimrsa Antibiotics Produced in Co-Culture by Extremophilic Fungi Through the Development of Fungal Artificial Chromosomes | ||||
Key People / Management
Nancy Keller
Kevin G Peters
Chengcang C Wu -- Founder
Kevin G Peters
Chengcang C Wu -- Founder
Company News
There are no news available.
